![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Azathioprine, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2017-008 - Rev 01
This Chemical Type CEP, issued on December 18, 2019, remains in force until October 12, 2023, ensuring its reliability within the pharmaceutical industry.
Substance Number 369 associated with this CEP further emphasizes